Expression of Stress Markers During Meth Treatment (EXPRESS+)

a study on Substance Abuse HIV/AIDS Methamphetamines

Summary

Eligibility
for males ages 18-45 (full criteria)
Healthy Volunteers
healthy people welcome
Location
at Los Angeles, California
Dates
study started
completion around
Principal Investigator
by Michael J Li, PhD

Description

Summary

This is a non-randomized behavioral trial that aims to investigate whether changes in inflammatory and type I IFN expression coincide with changes in methamphetamine use and viral load over the course of 12 weeks in HIV-positive people assigned male at birth with and without methamphetamine use disorder.

Official Title

Expression of Stress Markers in MSM Living With HIV Receiving Contingency Management for Methamphetamine Use Disorder

Details

This is a within-subjects, two-arm study with 35 HIV-positive people assigned male at birth receiving contingency management for treatment of methamphetamine use disorder and 20 HIV-positive people assigned male at birth serving as a non-substance-using healthy control (N=55 total). HIV-positive participants with methamphetamine use disorder who meet the eligibility criteria will be assigned to the contingency management treatment group. HIV-positive participants who do not use substances and meet the specific criteria will be assigned to the non-substance-using control group. Participants will be observed over 8 weeks, with another follow-up 4 weeks thereafter.

Keywords

Substance-Related Disorders, HIV, Contingency Management, Contingency Management for Methamphetamine Reduction

Eligibility

You can join if…

Open to males ages 18-45

For Contingency Management:

  1. Assigned male sex at birth
  2. 18 to 45 years of age
  3. Reports having sex with men in the past 12 months.
  4. HIV-positive (confirmed by certification or by HIV rapid test)
  5. Has an HIV care provider (last seen in the past 12 months)
  6. Has a current antiretroviral prescription
  7. Meets the DSM-5 criteria for methamphetamine use disorder using SCID-5
  8. Urine test is positive for methamphetamine within 30 days of their screening visit
  9. Seeking treatment for methamphetamine use disorder.
  10. Ability to attend twice weekly appointments for drug testing and treatment

For Non-substance-using Control:

  1. Assigned male sex at birth
  2. 18 to 45 years of age
  3. Reports having sex with men in the past 12 months.
  4. HIV-positive (confirmed by certification or by HIV rapid test)
  5. Has an HIV care provider (last seen in the past 12 months)
  6. Has a current antiretroviral prescription

You CAN'T join if...

For Contingency Management:

  1. Identifies as (cis- or transgender) female
  2. Reports another current or past substance use disorder
  3. Reports being in another intervention or clinical trial for substance use
  4. Positive test for opioids, cocaine, and/or MDMA

For Non-substance-using Control:

  1. Identifies as (cis- or transgender) female
  2. Positive test for methamphetamine, opioids, cocaine, and/or MDMA.
  3. Reports substance use (methamphetamine, opioids, cocaine, MDMA, hallucinogens, heavy alcohol use, and/or tobacco) in the past 6 months
  4. Reports past or current substance use disorder

Location

  • UCLA Vine Street Clinic accepting new patients
    Los Angeles California 90038 United States

Lead Scientist at UCLA

  • Michael J Li, PhD
    Assistant Professor-in-Residence, Family Medicine, Medicine. Authored (or co-authored) 28 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Los Angeles
ID
NCT05558345
Study Type
Interventional
Participants
Expecting 55 study participants
Last Updated